International

Asia Pacific

Trinity has extensive experience supporting healthcare clients with a wide range of commercial business issues in the APAC region

Home / International / Asia Pacific

Trinity supports global and local clients with commercialization strategies in the APAC region, in addition to supporting local clients with global expansion strategies

We leverage our expertise of APAC markets to develop recommendations and strategies pertinent to local needs
We bring APAC-specific and evidence-based insights to support our recommendations
We enhance communication and collaboration across global and APAC teams to ensure local needs are addressed

Supporting All Commercialization Needs
- Corporate Strategy
- Business Development
- New Product Planning
- Launch / Brand Planning
- Go-to-Market Strategy
- Pricing and Market Access
- Primary Market Research
- Strategic Competitive Intelligence
- Forecasting
Typical Business Questions
- What is the commercial / revenue potential of our product(s)?
- Which payer segments (national vs. provincial vs. hospital vs. private) should be targeted for P&MA?
- What are the key value drivers for HTA decisions? What strategies can we employ to achieve successful P&MA outcomes?
- What is our commercialization / registration pathway?
- How should we target and engage with our customer segments (e.g., city tiers, hospital tiers)?
- Which market entry business model should be adopted (e.g., go-alone, partner or out-license)?
- How can we expand our operations into global / local markets?
Local Experience in Specialized Markets
- Multilingual experts that are fluent in local language (Chinese, Japanese, Korean, etc.) to ensure optimal execution of research programs
- Extensive network of stakeholder types, including KOLs, providers, regulatory experts, payers and patients
- Ability to conduct market research in different formats (in-person, telephone, video platform, central facility, web survey)
Experience Across Most Therapeutic Areas

*Illustrative and not exhaustive; Abbreviations: PNH: Paroxysmal nocturnal hemoglobinuria; CVD: Cardiovascular diseases; GI: Gastrointestinal diseases; IBS: Irritable bowel syndrome; COPD: Chronic obstructive pulmonary disease; HAE: Hereditary angioedema; NASH: Nonalcoholic Steatohepatitis

Latest Asia Pacific Intelligence

White Papers

Cracking the Code of the Access Landscape in China

As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.  In this white […]

Blog

Japan’s Latest Drug Pricing Policy Updates: Key Changes and Expected Impact

A series of new drug pricing reforms came into effect in Japan in April 2022, to encourage innovation and ensure the transparency and predictability of drug pricing in the future. These include updates to the cost-accounting pricing methodology, an expansion of the scope of the Price Maintenance Premium (PMP)…

Webinars

Dragon’s Offer: Imparting Wisdom About Market Access Through the NRDL in China

What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update? The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on…

Watch Now

View All APAC Thought Leadership